Clincosm LogoSign in Get a demo

immunotherapy

Showing 1 - 25 of 158
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

Not yet recruiting
  • Carcinoma
  • +7 more
  • (no location specified)
Nov 12, 2023

NLR and Its Association With Efficacy of Immunochemotherapy in

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Nov 10, 2023

    Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue Trial in Warsaw (Pembrolizumab, Eftilagimod alpha)

    Recruiting
    • Neoadjuvant
    • +3 more
    • Pembrolizumab, Eftilagimod alpha
    • Warsaw, Poland
      Maria Sklodowska-Curie National Research Institute of Oncology
    Nov 7, 2023

    Head and Neck Squamous-cell Carcinoma

    Not yet recruiting
    • Squamous Cell Carcinoma of Head and Neck
    • +2 more
      • (no location specified)
      Nov 5, 2023

      Radiotherapy, Immunotherapy, Liver Metastases Trial in Shanghai (SBRT, Chemotherapy, PD-1 antibody)

      Recruiting
      • Radiotherapy
      • +3 more
      • SBRT
      • +2 more
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Nov 2, 2023

      Cervical Cancer, Induction Chemo, Immunotherapy Trial in Tianjin (Toripalimab)

      Recruiting
      • Cervical Cancer
      • +2 more
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Institute & Hospital
      Oct 16, 2023

      Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

      Not yet recruiting
      • Liver Diseases
      • +4 more
      • bTAE-HAIC
      • +2 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Sep 30, 2023

      Cancer, Solid Tumor, Thromboembolism Trial in Tripoli (Palbociclib, Rivaroxaban, SNP)

      Recruiting
      • Cancer
      • +12 more
      • Tripoli, North Lebanon, Lebanon
      • +1 more
      Oct 5, 2023

      NSCLC, Neoadjuvant Therapy, Radiotherapy Trial in Yangzhou (drug, radiation, other)

      Recruiting
      • Non-small Cell Lung Cancer
      • +3 more
      • Yangzhou, Jiangsu, China
        People's hospital of northern jiangsu
      Sep 26, 2023

      Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

      Not yet recruiting
      • Liver Diseases
      • +4 more
      • bTAE-HAIC
      • +2 more
      • Guanzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Sep 24, 2023

      Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy Trial in Wuhan (CTV omitted or delineated)

      Not yet recruiting
      • Advanced Non-Small Cell Squamous Lung Cancer
      • +2 more
      • CTV omitted or delineated
      • Wuhan, Hubei, China
        Hubei Cancer Hospital
      Sep 7, 2023

      Wheat Hypersensitivity, Immunotherapy Trial in Bangkoknoi (Wheat (Four times per week))

      Recruiting
      • Wheat Hypersensitivity
      • Immunotherapy
      • Wheat (Four times per week)
      • Bangkoknoi, Bangkok, Thailand
        Siriraj Hospital
      Sep 12, 2023

      Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy Trial in Wuhan (CTV omitted or delineated)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • +3 more
      • CTV omitted or delineated
      • Wuhan, Hubei, China
        Hubei Cancer Hospital
      Sep 1, 2023

      Colon Cancer, Neoadjuvant Therapy, Immunotherapy Trial in Guangzhou (Envafolimab, CAPEOX)

      Recruiting
      • Colon Cancer
      • +2 more
      • Guangzhou, Guangdong, China
        Sun Yat-Sen University Cancer Center
      Aug 26, 2023

      Symptoms Based on Patient-reported Outcomes in Immunotherapy for

      Not yet recruiting
      • Esophageal Cancer
      • +2 more
        • Guangzhou, Guangdong, China
          Guangdong Provincial People's Hospital
        Aug 24, 2023

        HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

        Recruiting
        • HER2-positive Gastric Cancer
        • Immunotherapy
        • Disitamab Vedotin combined with fruquintinib and Tislelizumab
        • Shanghai, Shanghai, China
          Fudan University Shanghai Cancer Center
        Aug 8, 2023

        Small Cell Lung Cancer, Immunotherapy Trial in Changsha (chronic psychological stress)

        Recruiting
        • Small Cell Lung Cancer
        • Immunotherapy
        • chronic psychological stress
        • Changsha, Hunan, China
          Department of Oncology, The Second Xiangya Hospital, Central Sou
        Jul 22, 2023

        Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)

        Recruiting
        • Biliary Tract Neoplasms
        • Immunotherapy
        • Beijing, Beijing, China
          Chinese Academy of Medical Sciences & Peking Union Medical Colle
        Jul 6, 2023

        Pre-transplant ICI Exposure and Post-transplant Graft Rejection

        Recruiting
        • Graft Rejection
        • +3 more
        • Immune checkpoint inhibitor
        • Guangzhou, Guangdong, China
          Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
        Jun 21, 2023

        Omitting Clinical Target Volume in Radical Treatment of

        Not yet recruiting
        • Immunotherapy
        • +3 more
        • IMRT+adjuvant immunotherapy
        • (no location specified)
        Jun 9, 2023

        Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)

        Recruiting
        • Immunotherapy
        • Second-line Treatment
        • Guizhou, ZunYi, China
          The Second Affiliated Hospital of Zunyi Medical University
        Jun 14, 2023

        Efficacy and Safety of ICIs as First-line Therapy for Advanced

        Not yet recruiting
        • Malignant Tumor
        • +2 more
          • Chongqing, Chongqing, China
            the second affiliated hospital of Army medical university
          May 16, 2023

          Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

          Not yet recruiting
          • Androgen-Independent Prostatic Cancer
          • +8 more
          • lorigerlimab
          • +2 more
          • (no location specified)
          May 4, 2023

          Colon Cancer, Immunotherapy Trial in Chongqing (Terelizumab, CapeOx)

          Not yet recruiting
          • Colon Cancer
          • Immunotherapy
          • Chongqing, China
            Daping hospital
          Apr 16, 2023

          Immunotherapy, Chemo Trial in Guandong (Camrelizumab)

          Recruiting
          • Immunotherapy
          • Chemotherapy
          • Guandong, Guangdong, China
            Nanfang Hospital, Southern Medical University
          Apr 22, 2023